Product Compliance And Certification For Infant Formula In Canada

Scope and evidence must be confirmed before any paid tests or filings.

Infant formula in Canada is not cleared by one generic “certification”. The launch decision joins Health Canada’s product-specific premarket requirements under the Food and Drug Regulations (FDR), compositional and evidence requirements, Canadian label rules and—where activities trigger them—Canadian Food Inspection Agency (CFIA) licensing, preventive controls and traceability under the Safe Food for Canadians framework. These are separate gates; an overseas authorization does not substitute for them.

Classify the product before choosing a route

First identify the intended consumer, whether the product replaces human milk, its physical format and the exact manufacturing history. Do not treat every food marketed to babies as infant formula.

Product / proposed change	Classification question	Practical decision
Powder, concentrate or ready-to-feed substitute	Is it intended as a partial or total substitute for human milk?	Treat as infant formula; check Division 25 and whether it is new to Canada.
Preterm or allergy-oriented specialty formula	Is the formula for a defined medically vulnerable infant group?	Remains within infant-formula controls; match the safety and nutritional-adequacy evidence to that population.
Human milk fortifier	Is it added to human milk rather than used alone as a substitute?	Assess the distinct fortifier provisions in Division 25; do not use the ordinary infant-formula route by default.
Infant cereal or fruit purée	Does it complement feeding rather than replace human milk?	Assess the relevant infant-food and general food rules, not an automatic formula notification.
Existing formula, new ingredient or facility	Has an ingredient, ingredient level, process, packaging or manufacturing site changed?	Perform and document a major-versus-minor change assessment before assuming the existing clearance covers it.

Under the Canadian definition, a formula is “new” if it is made for the first time, sold in Canada for the first time, or made for the first time by a particular manufacturer. A familiar formulation or an overseas brand does not settle the Canadian product/manufacturer classification (FDR B.25.045).

A human milk fortifier has its own Division 25 pathway. Unlike the formula notification timing rule, CFIA states that sale or advertising of an HMF requires ministerial authorization; assess B.25.010–B.25.018 separately rather than extrapolating the 90-day infant-formula provision.

For human milk fortifiers, the CFIA describes restricted access: outside hospitals, supply to an individual requires a written order from a physician or, where authorized, a nurse practitioner or dietitian. Do not use ordinary retail-formula assumptions for fortifiers.

Five regulatory gates for Canadian infant formula

Gate	Authority / key test	Evidence or launch hold
Composition and claims	FDR Division 25; permitted ingredients, nutrients and nutritional adequacy	Formula/specification comparison; resolve deficiencies before submission or labelling.
New product or major change	Health Canada; FDR B.25.046 or B.25.048	Signed manufacturer notification, statutory notice-period analysis and documented Health Canada review status; a favourable letter is recommended but is not a universal legal precondition after the notice period.
New ingredient	Health Canada; determine novel-food or new-infant-formula-ingredient (NIFI) route	Resolve ingredient safety pathway before treating its use in formula as acceptable.
Making / importing / interprovincial trade	CFIA; SFCR licensing, controls and records according to actual activities	Correct SFC licence and applicable preventive control, traceability and recall arrangements.
Canadian consumer pack	FDR Division 25 plus general Canadian food-labelling rules	Bilingual mandatory information, formula-specific nutrient declarations, expiry and use directions.

New ingredients: law versus guidance. If an ingredient is a “novel food” under FDR Division 28, the applicable statutory novel-food notification rules must be addressed. For a non-novel ingredient not previously used in Canadian infant formula, Health Canada describes a separate new infant food ingredient (NIFI) safety review; its modernization materials characterize this separate NIFI review as voluntary under the current regulations, not a compulsory standalone authorization. In either case, the manufacturer must substantiate the ingredient’s safety for infants and the finished formula’s compliance; seek a novelty determination when uncertain.

Premarket timing: notification is not a universal certificate

For a new infant formula or a formula with a major change, B.25.046/B.25.048 require manufacturer notification at least 90 days before sale or advertising, subject to the statutory provision permitting an earlier sale when the Minister confirms in writing that the notification is satisfactory. Health Canada describes its successful review outcome as a product-specific Letter of No Further Questions. Neither filing nor the mere passage of 90 days establishes that every other legal condition has been met.

The updated December 2025 guidance separately describes a 90-day active-review service standard for the vast majority of complete submissions; questions and response intervals are not active-review time. This is not a guaranteed clearance date. An existing formula is not automatically exempt: decide whether the Canadian product is new or whether a change meets the defined major-change test. Minor changes still require a documented safety/compliance assessment; the manufacturer bears that responsibility.

Keep the legal distinction precise: B.25.046(3) and B.25.048(3) expressly allow earlier sale following written confirmation that the notification is satisfactory. Health Canada describes its post-review letter as a practical review outcome, not a general third-party certification. The 90-day advance-notice rule and the 90 days of active review measure different things.

Do not turn the review letter into a mandatory authorization. Under the current wording of B.25.046(1) and B.25.048(1), the statutory restriction for infant formula is notification at least 90 days before sale or advertising; the provisions do not themselves mandate completion of Health Canada’s review or receipt of a Letter of No Further Questions once that period has passed. Health Canada explicitly says manufacturers usually wait for the letter but that the regulations do not require it. Written confirmation of a satisfactory notification is, however, necessary to use the earlier-than-90-days exception in subsection (3). Expiry of the notice period does not establish product safety, ingredient legality, adequate nutrition, compliant labelling, a valid CFIA licence or immunity from enforcement. Do not use the passage of time as scientific clearance; seek product-specific Health Canada advice before considering sale without a favourable review outcome. Human milk fortifiers have a different rule requiring ministerial authorization.

Formula-specific evidence: what to collect

Build one version-controlled file per formulation, format, intended population and relevant manufacturing configuration. For a new formula, the statutory notification elements under B.25.046(2) include:

Product identity, selling name, responsible manufacturer and every production establishment; identify any contractor.
Quantified formulation; nutrient, microbiological and physical specifications for ingredients and the finished formula, with supplier certificates and test methods.
Manufacturing flow and hazard controls, ingredient/finished-product testing, process validation, hygiene, packaging controls and lot identification.
Evidence of nutritional adequacy for the intended infants, including growth/tolerance and protein-quality evidence as applicable; clinical evidence needs depend on the specific formula and claims.
Stability and expiry-date test results, packaging description, preparation/use instructions, full label text and inserts.
For a major change, a change description, adequacy evidence and evidence that the change has not adversely affected the product (B.25.048(2)).

Do not assume a Codex, EU or US specification, a laboratory certificate or private quality-system certificate replaces the Canadian dossier. Review food-additive permissions and any novel ingredient assessment separately. A first-use packaging material can require a specific Health Canada packaging assessment; verify applicability rather than treating every packaging change as automatically minor.

Packaging is not just an artwork issue: section 4.11 of the December 2025 Health Canada submission guide asks for an issued Bureau of Chemical Safety letter of no objection for packaging-material acceptability. Treat this as the guide’s submission expectation, evaluate the actual food-contact material under Division 23, and confirm the applicable route rather than calling it an automatic certification of the complete formula.

Canadian label and lot-release checks

Before artwork lock and batch release, reconcile the submitted label text, final packaging and actual prepared-product composition. CFIA’s product-specific guide distinguishes infant formula from a standard packaged food:

Use the required common name “infant formula” and check English/French mandatory-label information; additional language rules may apply where marketed.
Use the Division 25 nutrient-content declaration rather than a standard “Nutrition Facts / Valeur nutritive” heading; a front-of-package nutrition symbol is prohibited on infant formula.
Provide adequate preparation, use and after-opening storage instructions, and a supported expiration date. Do not sell after that expiry date.
Substantiate specialty, allergen, growth and other claims; compare recipe, nutrient calculations, directions and packaging against the reviewed product.

For formula, Division 25 nutrient declarations cover quantities per 100 g or 100 mL as sold and per stated quantity ready to serve. Do not transplant a conventional food Nutrition Facts heading or an older foreign nutrient panel. CFIA also restricts nutrient-superiority representations; an iron-content claim has its own statutory condition under B.25.058.

An iron-content claim beyond simply declaring the amount is prohibited unless the formula contains at least 1 mg of iron per 100 available Calories (B.25.058). Meeting that threshold alone does not validate a superior-development claim; check the broader misleading-claims and substantiation rules.

Import and manufacturing responsibilities

For imports, CFIA specifies the SFC licence category manufactured food → infant foods for liquid or powdered formula (and human milk fortifiers), not for infant cereal or purées. Identify the importer of record and each manufacturer/packer; confirm which party holds the SFC licence for its activities. CFIA expects applicable preventive controls, traceability and recall procedures, and may verify the relevant Health Canada product letter. Imported goods must satisfy Canadian rules even if lawfully sold abroad.

Freeze the intended use, exact recipe, supplier list, plant, format and package; classify formula versus fortifier versus complementary food.
Compare Division 25 composition and ingredient status; seek early Health Canada input for uncertain novel ingredients, specialties or major changes.
Prepare the manufacturer’s product-specific submission and evidence; do not schedule launch solely from the 90-day number.
Before sale or advertising, verify the valid statutory notification period or a written early-sale confirmation, Health Canada review correspondence and unresolved objections, applicable CFIA licence and controls, final Canadian label and lot-release evidence; for HMF, verify ministerial authorization.

Change control and next safe action

A moved production site, altered drying step, new protein source or different packaging technology can affect the notified product even when the brand is unchanged. Keep a change log linking the old/new specification, safety rationale, evidence, label revision and decision on another submission. A simple translation correction may be minor, but it must still be evaluated and the Canadian label must remain compliant. Health Canada’s 2025–2026 consultation proposed changes to Divisions 24/25; proposals are not enacted requirements. Verify the consolidated regulations before launch.

For jurisdiction-specific alternatives, see the separate routes for infant formula in the United Kingdom and infant formula in the United States; neither is proof of Canadian market access.

Frequently asked questions

Does US or EU authorization allow a formula to be sold in Canada?

No. Determine whether it is a new Canadian infant formula, complete the relevant Health Canada pathway, and satisfy Canadian composition, labelling and CFIA obligations.

May sales begin automatically 90 days after filing?

Not automatically as a blanket permission. For infant formula, completion of a compliant 90-day advance-notification period does not itself require a final Health Canada letter, but it proves neither safety nor compliance with the other rules; a written satisfactory notice is required to sell earlier. Human milk fortifiers require ministerial authorization.

Does moving a plant trigger another review if the recipe is identical?

Potentially. A new facility or process can affect safety; assess the major-change definition and Health Canada facility guidance before transferring production.

Is cereal for a six-month-old regulated as infant formula?

Not just because it is intended for infants. A complementary cereal is different from a substitute for human milk and follows its applicable food provisions.

Can a distributor reuse a foreign pack with a translated sticker?

Only after confirming the full Canadian label, composition, instructions and product-specific submission alignment. A sticker alone cannot cure an unreviewed formula or missing CFIA obligations.